Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic

Neurologist

Volumn 18, Issue 2, 2012, Pages 102-107

  Adcock, Amelia K ^a   Lee Iannotti, Joyce K ^a   Aguilar, Maria I ^a   Hoffman Snyder, Charlene R ^a   Wingerchuk, Dean M ^a   Wellik, Kay E ^a   Demaerschalk, Bart M ^a  

^a MAYO CLINIC   (United States)

Author keywords

anticoagulants; atrial fibrillation; critically appraised topic; dabigatran; evidence based medicine; healthcare costs; healthcare rationing; medical economics; stroke; warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

AGED; ARTICLE; BRAIN ISCHEMIA; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART ATRIUM FIBRILLATION; HUMAN; LIBRARIAN; LOW DRUG DOSE; NEUROLOGIST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MALE; STROKE; WARFARIN;

EID: 84858144929     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e318247bcb6     Document Type: Article

References (40)

1. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
2. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285: 2370-2375. (Pubitemid 32424106)
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
5. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906. (Pubitemid 44175743)
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867. (Pubitemid 351650486)
7. Hart RG. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart. 1999;82:539-540. (Pubitemid 29515442)
8. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26:2422-2434. (Pubitemid 41552972)
9. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.
10. Baker WL, Cios DA, Sander SD, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the united states. J Manag Care Pharm. 2009;15:244-252.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY steering committee and investigators. dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
12. Carro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004; 10(14 suppl):S451-S458.
13. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
14. Muennig P. Cost-effectiveness Analyses in Health: A Practical Approach. San Francisco, CA: John Wiley & Sons; 2008.
15. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectivenss of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11.
16. Sonnenberg F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338. (Pubitemid 24013155)
17. Thomson Healthcare (Firm). Red Book. Montvale, NJ: Thomson PDR; 2007:v.
18. Drummond MF, Sculpher MJ, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press; 2005.
19. Berg AM. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:570, author reply 570-571.
20. Detsky AS, Naglie IG. A clinician's guide to cost-effective analysis. Ann Intern Med. 1990;113:147-154.
21. Johannesson M, O'Conor RM. Cost-utility analysis from a societal perspective. Health Policy. 1997;39:241-253. (Pubitemid 27112427)
22. Waterman AD, Milligan PE, Bayer L, et al. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm. 2004;61:1258-1264. (Pubitemid 39481461)
23. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
24. Edwards DB, Silerberg J. Letter: dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:570-571.
25. Ghanny S, Warkentin TE, Crowther MA. Reversing anticoagulant therapy. Curr Drug Discov Technol. 2011;1570-1638.
26. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol. 2004; 41(1 suppl 1):65-69.
27. Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2011;8:e1-e8.
28. Ganetsky M, Babu KM, Salhanick SD, et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7:281-287.
29. Freeman JV, Turakhia MP. Letter: dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:570-571.
30. Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791-1800.
31. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
32. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108:1447-1452.
33. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005; 293:699-706. (Pubitemid 40216039)
34. Wallenstin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ration control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-983.
35. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not lower dose of dabigatran. N Engl J Med. 2011;364:1788-1790.
36. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168-2175.
37. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343.
38. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123: 2562-2570.
39. Sorenson SV, Kansal AR, Connolly SJ. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908-915.
40. Eerenberg E, Kamphuisen P, Sijpkens K, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation. 2011;124:1573-1579.